Home Cart Sign in  
Chemical Structure| 607-80-7 Chemical Structure| 607-80-7

Structure of Sesamin
CAS No.: 607-80-7

Chemical Structure| 607-80-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sesamin is a natural product derived from sesame seeds, acting as a potent serum lipid-lowering food component.

Synonyms: Fagarol; Fsesamin; Sezamin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sesamin

CAS No. :607-80-7
Formula : C20H18O6
M.W : 354.35
SMILES Code : [H][C@]12[C@]([C@@H](C3=CC=C(OCO4)C4=C3)OC2)([H])CO[C@@H]1C5=CC=C6OCOC6=C5
Synonyms :
Fagarol; Fsesamin; Sezamin
MDL No. :MFCD00216134
InChI Key :PEYUIKBAABKQKQ-AFHBHXEDSA-N
Pubchem ID :72307

Safety of Sesamin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Yeast cells 100 µM 48 hours SrCYP92B14 oxidized (+)-sesamin primarily to (+)-sesaminol, with minimal production of (+)-sesamolin. PMC7756453
Yeast cells 100 µM 60 min Failed to catalyze the reaction PMC5735135
BV-2 cells 1, 10, 50 μM 24 hours Sesamin protected BV-2 cells from KA-induced injury by reducing LDH release and increasing cell viability PMC3129306
PC12 cells 0.1, 0.5, 1.0, 2.0 μM 24 hours Sesamin protected PC12 cells from KA-induced injury by reducing LDH release and increasing cell viability PMC3129306
BEnd.3 cells 50 μmol/L 1 hour To evaluate the protective effect of sesamin in alleviating the loss of ZO-1 induced by stretch injury. Sesamin pretreatment significantly alleviated the loss of ZO-1 in bEnd.3 cells after stretch injury. PMC5672062
Human bone marrow mesenchymal stem cells (BMSCs) 0.5 μM 24 hours Sesamin regulated chondrogenesis of BMSCs by activating ERα signaling and downstream BMP2 and SOX9 expression. PMC9147588
Human umbilical vein endothelial cells (HUVECs) 0.5 μM 3 and 6 hours Sesamin significantly promoted in vitro tube formation activity of HUVECs, and this promoting effect was attenuated by ERα inhibitor. PMC9147588
Human skin fibroblasts (Hs68 cells) 10 μM and above Sesamin significantly inhibited UVB-induced intracellular ROS generation at concentrations of 10 μM and above. PMC6769638
Human skin fibroblasts (Hs68 cells) 5–50 μM Sesamin showed no cytotoxicity to Hs68 cells at concentrations of 5–50 μM, with cell viability over 95%. PMC6769638
MIN6 cells 50 or 100 μM 24 hours To investigate the effects of sesamin on AGEs-induced insulin secretion, cell apoptosis, ROS production, and NADPH oxidase expression and activity in MIN6 cells. Results showed that sesamin significantly ameliorated AGEs-induced insulin secretion defects, reduced cell apoptosis and ROS production, and downregulated NADPH oxidase expression and activity. PMC4488808
RAW264.7 cells 0-10 μM 3 days Sesamin inhibits osteoclastogenic differentiation of RAW264.7 cells by deactivating NF-κB signaling pathway. PMC8704418
Mouse bone marrow mesenchymal stem cells (BMSCs) 1-10 μM 3 days Sesamin promotes osteogenic differentiation of BMSCs by activating Wnt/β-catenin signaling pathway. PMC8704418
NIT-1 pancreatic β-cells 400, 200, 100 µg/mL 24 hours Sesamin significantly reversed STZ-induced NIT-1 cell viability loss, increased insulin secretion, enhanced SOD, GSHpx activities and GSH content, reduced MDA, NO, NOS, and iNOS levels, and improved cell morphology. PMC3546733
GH3 cells 10 µM Sesamin further suppressed the CBN-induced decrease in peak INa amplitude PMC7827714

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
FVB mice and Sprague-Dawley rats KA-induced status epilepticus model Oral 15 mg/kg or 30 mg/kg Once daily for 3 days Sesamin significantly reduced KA-induced oxidative stress and mortality, and increased plasma α-tocopherol levels PMC3129306
Mice CCl4-induced liver injury model Oral (sesamin), Intraperitoneal (SC1) 25 mg/kg Twice administration (1 h before and 7 h after CCl4 injection) Sesamin and SC1 significantly suppressed CCl4-induced elevation of liver injury markers (AST, ALT, LDH) and inflammatory responses (TNFα, MCP-1), and these effects were abolished in ANX A1 knockout mice. PMC7033200
C57BL/6 mice Traumatic brain injury (TBI) model Intraperitoneal injection 30 mg/kg/d Once daily until the animals were sacrificed To evaluate the protective function of sesamin on BBB disruption after TBI. Sesamin treatment significantly attenuated CCI-induced brain edema, tissue hemoglobin levels, Evans blue extravasation, and AQP4 expression levels, and significantly alleviated CCI-induced loss of tight junction proteins ZO-1 and occludin. PMC5672062
C57BL/6 mice Osteoporotic fracture model Oral gavage 80 mg/kg/day Once daily for 14 or 28 days Sesamin markedly improved callus formation and increased the cartilaginous area at the early-stage, as well as narrowed the fracture gap and expanded callus volume at the late-stage fracture healing site of the OVX mice femur. Furthermore, the angiogenesis at the osteoporotic fracture site was also significantly improved by sesamin treatment. PMC9147588
Hairless mice (BALB/cAnN.Cg-Foxn1nu/CrlNarl) UVB-induced skin photodamage model Topical application 50 μM and 200 μM Once daily for 10 weeks Sesamin significantly reduced UVB-induced skin erythema, inflammation, and wrinkle formation, and restored skin collagen content. PMC6769638
C57BL/6J mice AGEs-induced pancreatic β-cell dysfunction and apoptosis model Oral 160 mg/kg body weight Once daily for four weeks To investigate the protective effects of sesamin on AGEs-induced pancreatic β-cell dysfunction and apoptosis. Results showed that sesamin significantly improved AGEs-induced glucose intolerance and insulin secretion defects, reduced pancreatic β-cell apoptosis and ROS production. PMC4488808
C57BL/6 mice Ovariectomy (OVX)-induced osteoporosis model Oral 80 mg/kg and 160 mg/kg Once daily for two months Sesamin attenuates bone loss in OVX mice osteoporosis model via down-regulating DANCR expression. PMC8704418
Mice Acetic acid-induced writhing response model Oral 50, 100, 200 mg/kg Single dose, 60 minutes before acetic acid injection To evaluate the analgesic activity of sesamin, results showed that sesamin at 200 mg/kg significantly inhibited acetic acid-induced abdominal writhing PMC4042560

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.82mL

0.56mL

0.28mL

14.11mL

2.82mL

1.41mL

28.22mL

5.64mL

2.82mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories